Pharsight

Drugs that contain Irinotecan Hydrochloride

1. Onivyde patents expiration

ONIVYDE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9782349 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 1 month from now)

US10722508 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 1 month from now)

US9724303 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 1 month from now)

US8992970 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 1 month from now)

US8329213 IPSEN INC Liposomes useful for drug delivery
Jan, 2027

(2 years from now)

US8147867 IPSEN INC Liposomes useful for drug delivery
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730891 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 1 month from now)

US8703181 IPSEN INC Liposomes useful for drug delivery
May, 2025

(1 year, 1 month from now)

US11369597 IPSEN INC Methods for treating pancreatic cancer using combination therapies
Jun, 2033

(9 years from now)

US9717724 IPSEN INC Methods for treating pancreatic cancer using combination therapies
Jun, 2033

(9 years from now)

US9492442 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US9364473 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US9339497 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US9452162 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US10980795 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Jun, 2033

(9 years from now)

US10456360 IPSEN INC Stabilizing camptothecin pharmaceutical compositions
Oct, 2036

(12 years from now)

US10993914 IPSEN INC Stabilizing camptothecin pharmaceutical compositions
Oct, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 13, 2031

Market Authorisation Date: 22 October, 2015

Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer; Treatment of...

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage

ONIVYDE family patents

Family Patents